GLP1R and type 2 diabetes mellitus: Trials looking at the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) and the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6), have shown that cardiovascular risk is lower in diabetic patients [10].